Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

키워드

참고문헌 (36)

1. Buckley PF, "Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic", Drugs Today (Barc), 39, pp.145~151 (2003)
2. Stahl SM, "Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications" (2008), Cambridge University Press
3. Han M, "Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission:implications for long-term drug efficacy and low extrapyramidal side-effects", Int J Neuropsychopharmacol, 12, pp.941~952 (2009)
4. Marder SR, "Aripiprazole in the treatment of schizophrenia:safety and tolerability in short-term, placebocontrolled trials", Schizophr Res, 61, pp.123~136 (2003)
5. Fountoulakis KN, "Acute dystonia with low-dosage aripiprazole in Tourette's disorder", Ann Pharmacother, 40, pp.775~777 (2006)
6. Lim HK, "Tardive dystonic symptoms associated with aripiprazole treatment", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.589~590 (2008)
7. Varkula M, "Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man", J Clin Psychopharmacol, 28, pp.245~247 (2008)
8. Greenaway M, "Focus on aripiprazole: a review of its use in child and adolescent psychiatry", J Can Acad Child Adolesc Psychiatry, 18, pp.250~260 (2009)
9. Blankenship K, "Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17years", Ped Health, 4, pp.375~381 (2010)
10. Findling RL, "Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study", J Clin Psychopharmacol, 28, pp.441~446 (2008)
11. McLaren JL, "Aripiprazole induced acute dystonia after discontinuation of a stimulant medication", J Clin Psychopharmacol, 30, pp.77~78 (2010)
12. Ono S, "Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine:case report and review of the literature", J Clin Pharm Ther, 37, pp.370~372 (2012)
13. Iñiguez SD, "Effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats", J Neural Transm (Vienna), 115, pp.97~106 (2008)
14. Bymaster FP, "Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit", hyperactivity disorder, 2002, pp.27, 699~711
15. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-IV-TR", American Psychiatric Association, ~ (2000)
16. Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
17. Mamo D, "Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study", Am J Psychiatry, 164, pp.1411~1417 (2007)
18. Soygür H, "Pharmacokinetic and pharmacodynamic characteristics of aripiprazole", Bull Clin Psychopharmacol, 18(Suppl 1), pp.1~6 (2008)
19. Bristol-Myers Squibb Company, "Aripiprazole (Abilify) prescribing information" (2006), Bristol-Myers Squibb Co and Otsuka America Pharmaceutical, Inc
20. Chen MH, "Aripiprazole-associated acute dystonia, akathisia, and parkinsonism in a patient with bipolar I disorder", J Clin Psychopharmacol, 33, pp.269~270 (2013)
21. Goga JK, "Acute laryngeal dystonia associated with aripiprazole", J Clin Psychopharmacol, 32, pp.837~839 (2012)
22. Ittasakul P, "Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient", Asian J Psychiatr, 5, pp.365~366 (2012)
23. van Harten PN, "Acute dystonia induced by drug treatment", BMJ, 319, pp.623~626 (1999)
24. Genro JP, "Attentiondeficit", hyperactivity disorder and the dopaminergic hypotheses, 2010, pp.10, 587~601
25. Prediger RD, "Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) --the spontaneously hypertensive rat (SHR)", Int J Neuropsychopharmacol, 8, pp.583~594 (2005)
26. Moon SJ, "Effect of atomoxetine on hyperactivity in an animal model of attention-deficit", hyperactivity disorder (ADHD), 2014, pp.9, e108918~
27. Hirose T, "Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist", J Med Invest, 52(Suppl), pp.284~290 (2005)
28. Burris KD, "Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors", J Pharmacol Exp Ther, 302, pp.381~389 (2002)
29. Mailman RB, "Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?", Curr Pharm Des, 16, pp.488~501 (2010)
30. Del Campo N, "The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit", hyperactivity disorder, 2011, pp.69, e145~e157
31. Párraga HC, "Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder", Int J Psychiatry Med, 37, pp.415~424 (2007)
32. Ledbetter M, "Atomoxetine use associated with onset of a motor tic", J Child Adolesc Psychopharmacol, 15, pp.331~333 (2005)
33. Garnock-Jones KP, "Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents", Paediatr Drugs, 11, pp.203~226 (2009)
34. Raike RS, "Animal models of generalized dystonia", NeuroRx, 2, pp.504~512 (2005)
35. Karakaş Uğurlu G, "Acute dystonia after using single dose duloxetine: case report", Psychiatry Investig, 10, pp.95~97 (2013)
36. Sauer JM, "Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome", J Pharmacol Exp Ther, 308, pp.410~418 (2004)

관련 논문AI추천